Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$27.8 million.

  • X4 Pharmaceuticals' Free Cash Flow rose 1831.22% to -$27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year increase of 3862.76%. This contributed to the annual value of -$131.2 million for FY2024, which is 3588.51% down from last year.
  • Per X4 Pharmaceuticals' latest filing, its Free Cash Flow stood at -$27.8 million for Q3 2025, which was up 1831.22% from -$29.9 million recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Free Cash Flow ranged from a high of -$12.4 million in Q1 2025 and a low of -$68.8 million during Q3 2023
  • For the 5-year period, X4 Pharmaceuticals' Free Cash Flow averaged around -$29.2 million, with its median value being -$26.5 million (2023).
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 25624.13% in 2023, then skyrocketed by 6315.66% in 2025.
  • X4 Pharmaceuticals' Free Cash Flow (Quarter) stood at -$19.1 million in 2021, then decreased by 0.32% to -$19.1 million in 2022, then tumbled by 45.25% to -$27.8 million in 2023, then dropped by 7.34% to -$29.8 million in 2024, then increased by 6.78% to -$27.8 million in 2025.
  • Its Free Cash Flow was -$27.8 million in Q3 2025, compared to -$29.9 million in Q2 2025 and -$12.4 million in Q1 2025.